Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 29775157)

  • 1. Blood-based biomarkers in breast cancer: From proteins to circulating tumor cells to circulating tumor DNA.
    Duffy MJ; McDermott EW; Crown J
    Tumour Biol; 2018 May; 40(5):1010428318776169. PubMed ID: 29775157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Circulating proteinic biomarkers and breast cancer].
    Mathelin C; Koehl C; Rio MC
    Gynecol Obstet Fertil; 2006; 34(7-8):638-46. PubMed ID: 16876456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case.
    Appierto V; Di Cosimo S; Reduzzi C; Pala V; Cappelletti V; Daidone MG
    Semin Cancer Biol; 2017 Jun; 44():106-116. PubMed ID: 28442298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of tumor markers and circulating tumors cells in the management of breast cancer.
    Saad A; Abraham J
    Oncology (Williston Park); 2008 Jun; 22(7):726-31; discussion 734, 739, 743-4. PubMed ID: 18619119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
    Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating plasma DNA and DNA integrity in breast cancer patients undergoing neoadjuvant chemotherapy.
    Lehner J; Stötzer OJ; Fersching D; Nagel D; Holdenrieder S
    Clin Chim Acta; 2013 Oct; 425():206-11. PubMed ID: 23916787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    Duffy MJ; Walsh S; McDermott EW; Crown J
    Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer.
    Kristiansen S; Jørgensen LM; Hansen MH; Nielsen D; Sölétormos G
    Biomed Res Int; 2015; 2015():986024. PubMed ID: 26339655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumour markers in breast cancer.
    Seregni E; Coli A; Mazzucca N;
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S15-22. PubMed ID: 15127239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of serum tumor markers for the diagnosis and follow-up of breast cancer.
    Barrenetxea G; Schneider J; Llorente MF
    Oncology; 1998; 55(5):447-9. PubMed ID: 9732223
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up.
    Sölétormos G; Nielsen D; Schiøler V; Skovsgaard T; Dombernowsky P
    Clin Chem; 1996 Apr; 42(4):564-75. PubMed ID: 8605674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in the treatment of cancer: opportunities and pitfalls.
    Melichar B
    Clin Chem Lab Med; 2013 Jul; 51(7):1329-33. PubMed ID: 23729626
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast.
    Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T
    Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor markers in breast cancer: accepted utilities and novel prospects.
    Stearns V; Yamauchi H; Hayes DF
    Breast Cancer Res Treat; 1998; 52(1-3):239-59. PubMed ID: 10066086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.